Showing 1 - 20 results of 7,973 for search '(( were ((tested decrease) OR (step decrease)) ) OR ( a ((large decrease) OR (marked decrease)) ))', query time: 0.57s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    “…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
  5. 5
  6. 6
  7. 7
  8. 8

    Demonstration of test steps. by Jin Zhu (164147)

    Published 2025
    “…The effectiveness of the proposed method was investigated by analyzing the precipitation of CaCO<sub>3</sub>, unconfined compressive strength (UCS) and permeability coefficient through aqueous solution test and sand column reinforcement test. Experimental results revealed that ferric ion incorporation significantly altered CaCO<sub>3</sub> crystal morphology and particle size distribution in aqueous solution test. …”
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    “…Anti-nucleocapsid response was similar at day 28 (mean difference in S/C ratio: 0.02 [95%CI: −0.11, 0.15], p = 0.75) and day 90 (mean difference in S/C ratio: 0.08 [95% CI: −0.05, 0.21], p = 0.22). Similar patterns were observed in all trials.</p><p>Conclusions</p><p>In patients hospitalized with COVID-19, treatment with nMAbs did not decrease long-term anti-nucleocapsid response compared to placebo, suggesting neutralizing therapies do not suppress the endogenous humoral immune response in this population.…”